Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT8010 and BAT1006 in Advanced Solid Tumors
NCT06376136Phase 2Active, not recruiting
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- May 2024
- Primary completion
- Feb 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of BAT8010 and BAT1006 in solid tumor (4 arms), sponsored by Bio-Thera Solutions, Ltd. Primary endpoints: Dose-limiting toxicity at 21 days, Vital signs at 1 year and 6 more. Started May 2024; status: active, not recruiting.
02
Drugs
BAT8010BAT1006
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06376136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06376136.